Abstract
Background Several population-based and cohort studies have reported an increased risk of second cancers in lymphoproliferative disorders (LPDs). The cause of second cancers in LPDs is probably multifactorial, and the relative contribution of treatments, genetic predisposition, and immune dysfunction typical of LPDs is still unclear. Patients and Methods We retrospectively studied 230 patients with Waldenström macroglobulinemia (WM) to assess the frequency, characteristics, and predictive factors of second cancers and to evaluate whether patients with WM are at higher risk of second cancers compared with an age- and sex-matched control population. Results In a competing-risk model, the cumulative incidence of solid cancers was 6% at 5 years, 11% at 10 years, and 17% at 15 years, whereas the incidence of hematologic malignancies was 4% at 5 years, 7% at 10 years, and 8% at 15 years. Compared with an age- and sex-matched population, the overall risk of second cancers was 1.7-fold higher than expected (95% confidence interval [CI], 1.22-2.38; P =.002). Patients with WM were at increased risk for diffuse large B-cell lymphoma (DLBCL) (standardized incidence ratio [SIR], 8.64; 95% CI, 3.88-19.22; P
| Original language | English |
|---|---|
| Pages (from-to) | 700-703 |
| Number of pages | 4 |
| Journal | Clinical Lymphoma, Myeloma and Leukemia |
| Volume | 13 |
| Issue number | 6 |
| DOIs | |
| Publication status | Published - Dec 2013 |
Fingerprint
Keywords
- Hematologic malignancies
- Second cancers
- Solid tumors
- Waldenström macroglobulinemia
ASJC Scopus subject areas
- Cancer Research
- Hematology
- Oncology
Cite this
Associated cancers in Waldenström macroglobulinemia : Clues for common genetic predisposition. / Morra, Enrica; Varettoni, Marzia; Tedeschi, Alessandra; Arcaini, Luca; Ricci, Francesca; Pascutto, Cristiana; Rattotti, Sara; Vismara, Eleonora; Paris, Laura; Cazzola, Mario.
In: Clinical Lymphoma, Myeloma and Leukemia, Vol. 13, No. 6, 12.2013, p. 700-703.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Associated cancers in Waldenström macroglobulinemia
T2 - Clues for common genetic predisposition
AU - Morra, Enrica
AU - Varettoni, Marzia
AU - Tedeschi, Alessandra
AU - Arcaini, Luca
AU - Ricci, Francesca
AU - Pascutto, Cristiana
AU - Rattotti, Sara
AU - Vismara, Eleonora
AU - Paris, Laura
AU - Cazzola, Mario
PY - 2013/12
Y1 - 2013/12
N2 - Background Several population-based and cohort studies have reported an increased risk of second cancers in lymphoproliferative disorders (LPDs). The cause of second cancers in LPDs is probably multifactorial, and the relative contribution of treatments, genetic predisposition, and immune dysfunction typical of LPDs is still unclear. Patients and Methods We retrospectively studied 230 patients with Waldenström macroglobulinemia (WM) to assess the frequency, characteristics, and predictive factors of second cancers and to evaluate whether patients with WM are at higher risk of second cancers compared with an age- and sex-matched control population. Results In a competing-risk model, the cumulative incidence of solid cancers was 6% at 5 years, 11% at 10 years, and 17% at 15 years, whereas the incidence of hematologic malignancies was 4% at 5 years, 7% at 10 years, and 8% at 15 years. Compared with an age- and sex-matched population, the overall risk of second cancers was 1.7-fold higher than expected (95% confidence interval [CI], 1.22-2.38; P =.002). Patients with WM were at increased risk for diffuse large B-cell lymphoma (DLBCL) (standardized incidence ratio [SIR], 8.64; 95% CI, 3.88-19.22; P
AB - Background Several population-based and cohort studies have reported an increased risk of second cancers in lymphoproliferative disorders (LPDs). The cause of second cancers in LPDs is probably multifactorial, and the relative contribution of treatments, genetic predisposition, and immune dysfunction typical of LPDs is still unclear. Patients and Methods We retrospectively studied 230 patients with Waldenström macroglobulinemia (WM) to assess the frequency, characteristics, and predictive factors of second cancers and to evaluate whether patients with WM are at higher risk of second cancers compared with an age- and sex-matched control population. Results In a competing-risk model, the cumulative incidence of solid cancers was 6% at 5 years, 11% at 10 years, and 17% at 15 years, whereas the incidence of hematologic malignancies was 4% at 5 years, 7% at 10 years, and 8% at 15 years. Compared with an age- and sex-matched population, the overall risk of second cancers was 1.7-fold higher than expected (95% confidence interval [CI], 1.22-2.38; P =.002). Patients with WM were at increased risk for diffuse large B-cell lymphoma (DLBCL) (standardized incidence ratio [SIR], 8.64; 95% CI, 3.88-19.22; P
KW - Hematologic malignancies
KW - Second cancers
KW - Solid tumors
KW - Waldenström macroglobulinemia
UR - http://www.scopus.com/inward/record.url?scp=84887995079&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84887995079&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2013.05.008
DO - 10.1016/j.clml.2013.05.008
M3 - Article
C2 - 24070824
AN - SCOPUS:84887995079
VL - 13
SP - 700
EP - 703
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
SN - 2152-2669
IS - 6
ER -